UK-based SME offers novel small molecule anti-fibrotic therapeutic
A UK-based SME has developed a novel small molecule that inhibits a cell signalling pathway that has a role in fibrosis. This molecule has shown potent efficacy combined with a good safety profile. The company is offering this molecule to other companies in the pharmaceutical space, especially those interested in fibrosis, for further development and commercialisation. It is envisaged that the partnership will take the form of a licensing agreement or a technical cooperation.
The SME is looking to partner with other companies operating in the pharmaceutical sector, especially those with an interest in fibrosis and fibrotic diseases. The SME will offer it's Wnt signalling pathway inhibitor molecule to partners under licence for the partner for further development, including clinical trials and to take to commercialisation. It is envisaged that the partnership will take the form of a licensing agreement. Technical cooperations will also be considered dependant on circumstances.
Certain diseases result in fibrosis of affected tissue. This 'scarring' causes reduced function compared to healthy tissue, which contributes to disease pathology. Wnt signalling is known to be important for tissue remodelling, such as that seen with fibrosis. Inhibition of the Wnt pathway is therefore likely to help prevent and / or reverse fibrosis in a way more beneficial than standard anti-inflammatory treatment. A UK-based SME has developed a novel small molecule that inhibits the Wnt signalling pathway. This molecule has been demonstrated to have potent efficacy on the Wnt pathway, shown to reduce indicators of fibrosis in a mouse model and have a good safety profile in both in vitro and in vivo models. The SME is looking to partner with other companies operating in the pharmaceutical space, especially those with an interest in fibrosis and fibrotic diseases. The SME will provide their novel molecule to a partner for further development and commercialisation. It is envisaged that the partnership will take the form of a licensing agreement or a technical cooperation depending on circumstances.
Advantages and innovations
The SME's novel small molecule has the following advantages: Potent inhibition of the Wnt pathway - in the nano-molar range in a cell assay system. Significant reduction of indicators of fibrosis such as connective tissue growth factor, type 1 collagen and fibronectin compared with vehicle controls in a mouse model of kidney fibrosis. Good safety and pharmacokinetic profiles in in vitro and in vivo models.
Under development/lab tested
Intellectual Property Rights (IPR)
Secret Know-how,Patent(s) applied for but not yet granted
Register your interest
How it works
- Tell us about yourself
- We’ll discuss with you
- We put the right partners in touch
EEN help you find the right partner, rather than you going it alone.
Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.
These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.
Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.
First we need to check you’re human.
Thank you for verifying your email. We have sent you a confirmation email containing a 6 digit verification code to unlock the form below